Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs ING Groep NV (ING) Price & Performance

CVS Health CorpTrade
ING Groep NVTrade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs ING Groep NV — how do they compare? CVS Health Corp trades at $104.86 (market cap $135.48B), while ING Groep NV trades at $32.76 (market cap $93.58B). The key difference: CVS Health Corp is the larger of the two by market cap, and ING Groep NV pays the higher dividend (3.86%). Which is the better fit depends on your goals.

CVSING
Market Cap
$135.48B$93.58B
Sector
HealthFinancials
52-Week High
$106.18$32.96
52-Week Low
$58.75$22.45
Enterprise Value
$202.02B
Dividend Yield
2.51%3.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.

The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.

ING Groep NV

ING trades at $32.30, down 0.28% on the day, with strong analyst support (62.5% buy ratings) and bullish technical signals. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $0.63 exceeding the $0.60 forecast. Revenue growth remains steady at $22.9B for 2025, while net income margin stands at 27.84%. Recent corporate developments include a new global subscription banking model and management board appointments.

The outlook remains positive given ING's earnings momentum, attractive valuation (P/E 12.95), and strategic initiatives. Key risks include negative operating cash flow trends and exposure to European banking sector volatility. With intrinsic value estimates around $34 from DCF analyses, the stock offers potential upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS

About ING Groep NV

The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.

Read more on ING